The RADAR (Risk-Adapted therapy Directed According to Response) trial is looking to recruit newly diagnosed myeloma patients suitable for high-dose therapy and stem cell transplantation.
The trial is investigating whether tailored treatment strategies for myeloma patients could optimise patient care, reduce the risk of early relapse, and increase life expectancy.
RADAR will tailor treatments to individual patients based on how well they respond to initial treatment and their myeloma’s genetic risk status (high or standard).
This approach gives UK patients with the highest risk of relapsing early (within 18 months of treatment) the opportunity to receive more intensive treatments not currently available through the NHS to help improve remission times.
This approach also gives UK patients with the lowest risk of relapsing an opportunity to stop treatment early, enjoy a treatment-free interval, and avoid longer-term side effects. This, again, is an option not currently available through the NHS.
Furthermore, the recent update to the protocol gives high-risk patients access to isatuximab (Sarclisa®), a targeted monoclonal antibody, as part of their induction, consolidation, and maintenance treatment.
The trial will provide evidence to support personalised myeloma treatment in routine care.
Recruitment for the study has opened at 84 sites across England, Scotland and Wales, including the University College Hospital in London and St James’ Hospital in Leeds.

Professor Kwee Yong, Principal Investigator of the RADAR trial, said:

“We are really excited that this brings, for the first time, stratified treatment for newly diagnosed patients according to genetic risk at baseline.  Treatment is then adjusted according to how well they respond.”

Read more about RADAR and other myeloma trials open to recruitment in the UK on the Myeloma UK Trial Finder.